Online inquiry

IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12878MR)

This product GTTS-WQ12878MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12878MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8618MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ7080MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ4847MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ13349MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ2494MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ12512MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ11180MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ6510MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CX-072
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW